Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
PHA – June 2022
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
